Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Genprex Inc (GNPX)

Genprex Inc (GNPX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 140,324
  • Shares Outstanding, K 38,871
  • Annual Sales, $ 0 K
  • Annual Income, $ -10,650 K
  • 60-Month Beta -0.81
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.98

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.21
  • Number of Estimates 1
  • High Estimate -0.21
  • Low Estimate -0.21
  • Prior Year -0.15
  • Growth Rate Est. (year over year) -40.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.46 +6.07%
on 09/11/20
4.47 -17.90%
on 09/01/20
-0.13 (-3.42%)
since 08/21/20
3-Month
2.81 +30.60%
on 07/14/20
4.50 -18.44%
on 07/23/20
+0.65 (+21.52%)
since 06/22/20
52-Week
0.23 +1,488.74%
on 12/11/19
7.03 -47.80%
on 02/25/20
+2.80 (+319.43%)
since 09/20/19

Most Recent Stories

More News
Genprex Names Seasoned IP Executive, Thomas C. Gallagher, as Senior Vice President of Intellectual Property and Licensing

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced...

GNPX : 3.62 (+0.28%)
Genprex Appoints William E. Gannon, Jr., MD, MBA, as Vice President of Regulatory Affairs

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced...

GNPX : 3.62 (+0.28%)
Genprex to Present at The LD 500 Virtual Conference

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced...

GNPX : 3.62 (+0.28%)
Genprex to Present at Proactive's One2One Virtual Investor Forum on August 4, 2020

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, announced today...

GNPX : 3.62 (+0.28%)
Advancements in Breast Cancer Research & Clinical Studies Producing Optimism for New Treatments

, /PRNewswire/ -- The triple negative breast cancer (TNBC) treatment market to grow at stellar CAGR through 2026. A  from Cole Market Research has stated that the ongoing advancements in cancer research...

ONCY : 1.7800 (-3.78%)
ONC.TO : 2.39 (-2.05%)
GNPX : 3.62 (+0.28%)
CRDF : 10.23 (-11.81%)
MRK : 82.65 (-0.58%)
LLY : 149.42 (-1.16%)
Genprex Receives USAN Approval of Non-Proprietary Name for Lead Drug Candidate

--Lead drug candidate for NSCLC now referred to as quaratusugene ozeplasmid or GPX-001

GNPX : 3.62 (+0.28%)
Genprex CEO to Interview Live on "The Big Biz Show"

Genprex, Inc. ("Genprex" or the "Company") (Nasdaq: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced...

GNPX : 3.62 (+0.28%)
Genprex Expands Manufacturing Program with Aldevron to Advance Oncoprex(TM) Clinical Development

--Manufacturing program supports upcoming clinical trials, including Oncoprex in combination with Tagrisso(R), which received FDA Fast Track Designation

GNPX : 3.62 (+0.28%)
Genprex Scheduled to Join Russell 3000(R) Index

Genprex, Inc. ("Genprex" or the "Company") (Nasdaq: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced...

GNPX : 3.62 (+0.28%)
Genprex to Present at the MoneyShow June Virtual Event

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, announced that...

GNPX : 3.62 (+0.28%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade GNPX with:

Business Summary

Genprex Inc. operates as a biotechnology company. It discovers and develops immunogene therapies for cancer treatment as well as clinical research, gene therapies, consulting and other related medical services. The company's initial product candidate is Oncoprex(TM) immunogene therapy which treats non-small...

See More

Key Turning Points

2nd Resistance Point 3.82
1st Resistance Point 3.72
Last Price 3.62
1st Support Level 3.54
2nd Support Level 3.46

See More

52-Week High 7.03
Fibonacci 61.8% 4.43
Fibonacci 50% 3.63
Last Price 3.62
Fibonacci 38.2% 2.83
52-Week Low 0.23

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar